by Daniel X. Thomas
EP 2 137 782 B1 relates to a device (claim 1) and a method (claim 11) for converting light energy into electrical energy and/or hydrogen by using a living plant for converting light energy into a feedstock for a microbial fuel cell.
The infringing device
Brief outline of the case
The patent was granted by the EPO and no opposition was filed.
by Daniel X. Thomas
EP 3 498 115 B1 relates to a vaporizing device, in other words, an e-cigarette.
EP 3 498 115 B1 has a parent application EP 3 430 921 as well as a grandparent application EP 3 086 671
Brief outline of the case
Procedure before the EPO
The patent was opposed at the EPO.
by Daniel X. Thomas
EP 3 167 888 B1 relates to the treatment of paroxysmal nocturnal hemoglobinuria patients with an inhibitor of complement component 5.
Claim 2 reads:
“A pharmaceutical composition comprising the antibody of claim 1.”
Claim 1 reads
“An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO: 2
and a light chain consisting of SEQ ID NO:4.”
According to the description SEQ ID NO: 2 represents the eculizumab heavy chain and SEQ ID NO:4 represents the eculizumab light chain.
by Daniel X. Thomas
I had the pleasure to be in person at a Conference organised by CEIPI on the UPC on : The UPC – The first year in review.
The present summary is by no means exhaustive and some figures might be incorrect as they result from notes taken on the fly.
Contribution n° 1 was given by Mrs Florence Butin,
by Daniel X. Thomas
EP 3 666 797 B1 relates to antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.
The case is interesting not only as is a decision taken by a Section of the Central Division, but an opposition is going on in parallel at the EPO for the patent at stake and for the patent resulting from a first divisional application.